Life Fest 2018: Pharma Panel: Apritinib Update for the GIST Patients & Caregivers
Pharma Panel: Overview of Promising Trials for GIST Blueprint Medicines View all life fest 2018 videos
GIST Updates from the ASCO Annual Meeting 2018
Executive Director, Norman Scherzer, and Real World Evidence Data Scientist, Dr. Yu Wang, of the Life Raft Group recently attended the ASCO (American Society of Clinical Oncologists) 2018 meeting in Chicago. Dr. Wang describes [...]
Deciphera Pharmaceuticals Announces the Start of Phase 3 Clinical Trial with DCC-2618 in GIST
On January 4th, 2018 Deciphera Pharmaceuticals, Inc, announced the start of the Phase 3 INVICTUS trial. This randomized trial is for 4th line GIST patients that have failed (or are intolerant) the [...]
It’s a Journey: Our Experience on Clinical Trials
By Jennifer Moore, LRG Member I was waiting in line to pick up a new prescription for Gleevec when my husband ran in and told me to forget it. After two surgeries, a year [...]
Why Do Cancer Patients Join Clinical Trials?
At the most basic level, cancer patients join clinical trials because of perceived value and perceived cost. In this context, perceived cost refers to more than just financial cost, although that is important. Perceived [...]
Clinical Trials Offer Hope for GIST Patients
The Life Raft Group Clinic Trials Database currently lists 31 trials that are open that are or could be of interest to GIST patients. Many of the most interesting of these new drugs are [...]
CTTI Meeting Promotes Innovation
Professor Dan Ariely The Clinical Trials Transformation Initiative (CTTI) held its quarterly Steering Committee meeting this past September in Washington DC, which focused largely on effective ways to increase adoption of clinical [...]
GIST Patient Community Update on BLU-285 Clinical Program
Dr. Anthony Boral, Chief Medical Officer of Blueprint Medicines, provided an update on the clinical development of BLU-285, an investigational medicine being developed for patients with advanced GIST. The presentation included an [...]
Loxo Oncology Announces Plans for LOXO-101
In a recent press release, Loxo Oncology announced an update on the status of their TRK (tropomyosin receptor kinase) inhibitor drug, larotrectinib (LOXO-101). Larotrectinib targets the NTRK genes, which encode for the TRK kinases. [...]
Quadruple-Negative GIST Tumors May Be More Likely To Harbor NF1 Mutations As Well
In a pre-print electronic publication of the July 7, 2016 edition of Clinical Cancer Research, a team of Italian researchers examined the link between “Quadruple-Negative” GISTs (those that do not exhibit KIT, PDGFRA, or BRAF [...]